SURMODICS INCSRDX

時価総額

$6.1億

PER

パフォーマンスコーティングと血管インターベンション医療機器の有力企業。潤滑性や薬物送達機能を持つコーティング技術とIVDを展開。2024年5月に合併契約締結、2024年8月13日に株主承認。米国・欧州を中心に展開。

	2011年 9月30日	2012年 9月30日	2013年 9月30日	2014年 9月30日	2015年 9月30日	2016年 9月30日	2017年 9月30日	2018年 9月30日	2019年 9月30日	2020年 9月30日	2021年 9月30日	2022年 9月30日	2023年 9月30日	2024年 9月30日
Net loss	-	-	-	-	-	-	-	-4	8	1	4	-27	-2	-12
Depreciation and amortization	7	3	3	3	3	5	6	6	7	7	8	9	9	9
Stock-based compensation	-	-	-	-	-	-	-	-	5	5	6	7	8	8
Noncash lease expense	-	-	-	-	-	-	-	-	-	-	0	1	1	1
Amortization of debt issuance costs	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Provision for credit losses	-	-	-	-	-	-	0	0	0	0	-0	0	0	0
Contingent consideration (gain) expense	-	-	-	-	-	2	-0	1	-0	-	-	-	-1	-
Deferred taxes	-6	-1	-0	-0	0	0	1	-2	-1	-1	2	5	-0	-0
Other	-	-	-	-	-	-0	-	-0	-0	-0	-0	-0	-0	1
Accounts receivable and contract assets	-	-	-	-	-	-	-	-	2	-3	2	2	1	5
Inventories	1	0	-0	-1	0	0	-0	1	1	1	1	5	3	0
Prepaids and other	-0	-0	0	0	-0	-0	1	2	2	-0	2	1	-	-5
Accounts payable	-	-	-	-	-	-	-	-	-1	-0	0	2	-0	-0
Accrued liabilities	-	-	-	-	-	-	-	-	-2	2	1	0	-1	-1
Income taxes	1	6	-1	0	-0	0	-0	-1	1	-2	0	-1	3	2
Deferred revenue	-	-	-	-	-	-	-	-	-4	-1	-1	-6	-2	-5
Net cash provided by (used in) operating activities	20	18	-	-	-	-	-	34	8	14	15	-17	11	0
Purchases of property and equipment	3	1	2	2	2	8	6	9	6	4	5	3	3	3
Payment for acquisition of intangible assets	-	-	-	-	-	-	-	-	-	-	1	-	-	-
Purchases of available-for-sale securities	51	44	-	-	-	-	-	-	-	-	-	-	4	25
Maturities of available-for-sale securities	-	-	-	-	-	-	-	-	-	-	-	-	-	26
Purchase of business, net of acquired cash	6	-	-	-	-	26	-	-	-	-	40	-	-	-
Net cash (used in) provided by investing activities	-9	30	-	-	-	-	-	-23	10	-9	-25	6	-7	-3
Payments on short-term borrowings	-	-	-	-	-	-	-	-	-	-	-	-	10	-
Proceeds from issuance of long-term debt	-	-	-	-	-	-	-	-	-	-	-	-	30	-
Payment of debt issuance costs	-	-	-	-	-	-	-	-	-	-	-	-	1	-
Issuance of common stock	1	0	0	1	1	0	0	2	1	2	3	1	1	1
Payments for taxes related to net share settlement of equity awards	-	-	-	-	-	-	-	5	3	3	3	1	1	2
Payments for acquisition of in-process research and development	-	-	-	-	-	-	-	-	-	1	0	1	1	1
Payments for acquisition-related deferred consideration	-	-	-	-	-	-	-	1	9	3	-	-	-	2
Net cash (used in) provided by financing activities	1	-55	-	-	-	-	-	-3	-11	-5	10	-0	18	-3
Effect of exchange rate changes on cash	-	-	-	-	-	-	-	-0	-0	0	-0	-1	0	0
Net change in cash and cash equivalents	-	-	-	-	-	-	-	7	7	0	0	-12	22	-5
Income Taxes Paid, Net	1	2	7	6	7	7	2	1	0	0	0	0	3	3
Cash paid for interest	-	-	-	-	-	-	-	-	-	-	0	0	3	3
Acquisition of property and equipment, net of refundable credits in other current assets and liabilities	-	-	-	-	-	-	-	1	0	-	-	-	0	-
Acquisition of property and equipment funded through accounts payable and accrued liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	-	-	-	-	-	-	-	-	-	1	0	2	-	1
Noncash or Part Noncash Acquisition, Debt Assumed	-	-	-	-	-	-	-	-	-	-	4	-	-	-